In spite of the sarky reply from Sponge, which adds nothing to...

In spite of the sarky reply from Sponge, which adds nothing to the discussion, my memory of the G v H studies is basically as follows. There was only a small number of sites involved with Duke Uni being the primary investigator site. The reason for this is because treatment for the disorder is
complex. and only carried out at a small number of locations within the USA. From MESO's point of view this has advantages ; they can run with
the product themselves with only a small sales force being required. It is also correct that, at least some insurance companies had given advanced approval to the treatment. With the 9-1 vote it looked a certainty. Ah well, lives lost but many will be saved in the future. Hope that this answers your queries.

Aplin